Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Authors = Houari Korideck

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
14 pages, 640 KiB  
Review
Novel Prodrugs for Targeting Diagnostic and Therapeutic Radionuclides to Solid Tumors
by Amin I. Kassis, Houari Korideck, Ketai Wang, Pavel Pospisil and S. James Adelstein
Molecules 2008, 13(2), 391-404; https://doi.org/10.3390/molecules13020391 - 18 Feb 2008
Cited by 12 | Viewed by 11423
Abstract
Most cancer therapeutics (chemo, radiation, antibody-based, anti-angiogenic)are at best partially and/or temporarily effective. In general, the causes for failure can besummarized as: (i) poor diffusion and/or nonuniform distribution of drug/prodrugmolecules in solid tumors; (ii) high drug concentration and retention in normal tissues(leading to [...] Read more.
Most cancer therapeutics (chemo, radiation, antibody-based, anti-angiogenic)are at best partially and/or temporarily effective. In general, the causes for failure can besummarized as: (i) poor diffusion and/or nonuniform distribution of drug/prodrugmolecules in solid tumors; (ii) high drug concentration and retention in normal tissues(leading to side effects); (iii) requirement for plasma-membrane permeability and/orinternalization of drug/prodrug molecules; (iv) low uptake of drug by tumor; (v) lack ofretention of drug within tumor (most have gradient-driven reversible binding); and (vi)multidrug resistance. We are developing an innovative technology that aims to surmountthese problems by actively concentrating and permanently entrapping radioimaging andradiotherapeutic prodrugs specifically within solid tumors. The approach will enablenoninvasive sensing (imaging) and effective therapy of solid tumors, allowing tumordetection, diagnosis, and treatment to be closely coupled (personalized medicine). Full article
(This article belongs to the Special Issue Prodrugs)
Show Figures

Figure 1

Back to TopTop